- Home
- IMMX vs IKNA Comparison
IMMX vs IKNA Comparison
Compare IMMX & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- IKNA
- Stock Information
- Founded
- IMMX 2014
- IKNA 2016
- Country
- IMMX United States
- IKNA United States
- Employees
- IMMX N/A
- IKNA N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- IKNA Health Care
- Exchange
- IMMX Nasdaq
- IKNA Nasdaq
- Market Cap
- IMMX 61.1M
- IKNA 63.7M
- IPO Year
- IMMX 2021
- IKNA 2021
- Fundamental
- Price
- IMMX $2.65
- IKNA $1.36
- Analyst Decision
- IMMX Strong Buy
- IKNA Strong Buy
- Analyst Count
- IMMX 1
- IKNA 1
- Target Price
- IMMX $7.00
- IKNA $4.00
- AVG Volume (30 Days)
- IMMX 137.1K
- IKNA 59.4K
- Earning Date
- IMMX 08-11-2025
- IKNA 08-07-2025
- Dividend Yield
- IMMX N/A
- IKNA N/A
- EPS Growth
- IMMX N/A
- IKNA N/A
- EPS
- IMMX N/A
- IKNA N/A
- Revenue
- IMMX N/A
- IKNA N/A
- Revenue This Year
- IMMX N/A
- IKNA N/A
- Revenue Next Year
- IMMX N/A
- IKNA N/A
- P/E Ratio
- IMMX N/A
- IKNA N/A
- Revenue Growth
- IMMX N/A
- IKNA N/A
- 52 Week Low
- IMMX $1.26
- IKNA $0.97
- 52 Week High
- IMMX $3.00
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- IMMX 61.44
- IKNA 53.81
- Support Level
- IMMX $2.16
- IKNA $1.31
- Resistance Level
- IMMX $2.80
- IKNA $1.42
- Average True Range (ATR)
- IMMX 0.17
- IKNA 0.05
- MACD
- IMMX 0.04
- IKNA -0.00
- Stochastic Oscillator
- IMMX 80.00
- IKNA 45.45
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.